TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME

TSC-203-A0201 is TScan’s fourth TCR-T cell product cleared for use in its solid tumor program, designed to enable customized, multiplexed TCR-T cell therapy

WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for TSC-203-A0201, a TCR-T targeting PReferentially expressed Antigen in Melanoma (PRAME). In addition to being expressed in ~90% of melanomas, PRAME is also frequently expressed in various other solid tumors, including ~90% of head & neck cancers and ~50% of non-small cell lung cancers. TSC-203-A0201 is specific for patients with HLA type A*02:01, which represents over 40% of people in the U.S. TSC-203-A0201 is the fourth TCR-T cleared for clinical development in the Company’s solid tumor program, following TSC-200-A0201, TSC-204-A0201, and TSC-204-C0702, which target human papillomavirus 16 (HPV16) presented on HLA type A*02:01, and MAGE-A1 presented on HLA types A*02:01 and C*07:02, respectively.

All four TCR-T cell products are designed to be used in combination with each other and are being developed under a single master clinical trial protocol. Each agent is an enhanced, autologous T cell therapy product that includes the cancer antigen-specific TCR, along with CD8α/ß to engage helper T cells and a dominant negative form of TGFß receptor II to promote T-cell persistence. Patients are administered specific combinations of TCR-T cell agents based on which targets and HLAs are expressed in their tumors. In the Phase 1 clinical trial, each agent will first be tested singly at two dose levels to establish safety, and then will be eligible to be combined with any other TCR-T cell product.

“We are thrilled to have a multiplexing strategy that allows us to customize treatments tailored to each patient’s tumor biology, particularly utilizing targets that are expressed in prevalent cancers such as melanoma, lung, and head and neck cancers,” said Debora Barton, M.D., Chief Medical Officer. “More importantly, customizable treatments may be crucial to achieve durable responses, overcome tumor heterogeneity, and resistance that develops from either target or HLA loss, which are commonly observed in these tumor types. A screening protocol to identify eligible patients has already been initiated and clinical trial start-up activities are underway to initiate clinical development for all four TCR-Ts in the ImmunoBank. We are excited about the potential to help patients with these prevalent solid tumors, where a high unmet need for effective treatments remains, and are on-track to treat the first patient with a TScan TCR-T and report preliminary data by the end of 2023.”